Go Pro
→ Elon Musk’s One Stock Retirement Plan (From Brownstone Research) (Ad)tc pixel Free APVO Stock Alerts

Aptevo Therapeutics (APVO) Competitors

Aptevo Therapeutics logo
$1.84 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.88 +0.04 (+2.17%)
As of 09/18/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

APVO vs. PLUR, NRSN, SQZ, BCLI, and BLRX

Should you buy Aptevo Therapeutics stock or one of its competitors? Aptevo Therapeutics's main competitors and comparable companies include Pluri (PLUR), NeuroSense Therapeutics (NRSN), SQZ Biotechnologies (SQZ), Brainstorm Cell Therapeutics (BCLI), and BioLineRx (BLRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aptevo Therapeutics compare to Pluri?

Aptevo Therapeutics (NASDAQ:APVO) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Aptevo Therapeutics' average media sentiment score of 0.75 beat Pluri's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aptevo Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pluri
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aptevo Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
Pluri -2,344.59%N/A -82.71%

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 0.4% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pluri has higher revenue and earnings than Aptevo Therapeutics. Pluri is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
Pluri$1.02M13.08-$23.82M-$2.45N/A

Aptevo Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Pluri has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pluri
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Pluri beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Aptevo Therapeutics compare to NeuroSense Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
NeuroSense TherapeuticsN/AN/A-$11.12M-$0.54N/A

NeuroSense Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
NeuroSense Therapeutics N/A N/A N/A

NeuroSense Therapeutics has a consensus price target of $170.00, indicating a potential upside of 2,577.17%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Aptevo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NeuroSense Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 0.4% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aptevo Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Aptevo Therapeutics' average media sentiment score of 0.75 beat NeuroSense Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aptevo Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroSense Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

NeuroSense Therapeutics beats Aptevo Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Aptevo Therapeutics compare to SQZ Biotechnologies?

SQZ Biotechnologies (NYSE:SQZ) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Aptevo Therapeutics has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
Aptevo Therapeutics N/A -201.49%-119.21%

Aptevo Therapeutics has lower revenue, but higher earnings than SQZ Biotechnologies. Aptevo Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A

SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 0.4% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aptevo Therapeutics had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for SQZ Biotechnologies. Aptevo Therapeutics' average media sentiment score of 0.75 beat SQZ Biotechnologies' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
SQZ Biotechnologies Neutral
Aptevo Therapeutics Positive

Summary

SQZ Biotechnologies beats Aptevo Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Brainstorm Cell Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Aptevo Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
Brainstorm Cell Therapeutics N/A N/A -519.50%

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 0.4% of Aptevo Therapeutics shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for Brainstorm Cell Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.75 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aptevo Therapeutics Positive
Brainstorm Cell Therapeutics Neutral

Summary

Aptevo Therapeutics beats Brainstorm Cell Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Aptevo Therapeutics compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

In the previous week, Aptevo Therapeutics had 1 more articles in the media than BioLineRx. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for BioLineRx. Aptevo Therapeutics' average media sentiment score of 0.75 beat BioLineRx's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
BioLineRx Neutral
Aptevo Therapeutics Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BioLineRx has higher revenue and earnings than Aptevo Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLineRx$1.18M10.23-$1.17M-$1.69N/A
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 0.4% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aptevo Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BioLineRx-502.08% -34.80% -18.27%
Aptevo Therapeutics N/A -201.49%-119.21%

BioLineRx has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Summary

BioLineRx and Aptevo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APVO vs. The Competition

Export
MetricAptevo TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.33M$3.88B$7.24B$12.95B
Dividend YieldN/A3.64%2.57%12.80%
P/E Ratio-0.0414.23275.4925.40
Price / SalesN/A1,440.84644.4486.30
Price / CashN/A108.9076.2551.42
Price / Book0.1115.4510.466.33
Net Income-$25.97M-$22.86M$3.49B$358.33M
7 Day Performance1.10%-1.21%0.59%1.12%
1 Month Performance-33.33%-3.29%-1.74%-2.39%
1 Year Performance-94.19%37.74%18.13%5.35%

Aptevo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APVO
Aptevo Therapeutics
0.743 of 5 stars		$1.84
flat		N/A-94.2%$3.33MN/AN/A33
PLUR
Pluri
0.2399 of 5 stars		$1.18
-5.6%		N/A-77.5%$13.15M$1.34MN/A150
NRSN
NeuroSense Therapeutics
2.1704 of 5 stars		$0.35
+4.6%		$8.50
+2,348.2%		-74.0%$13.11MN/AN/A10
SQZ
SQZ Biotechnologies
N/A$0.02
flat		N/AN/A$12.83M$18.16MN/A1,620
BCLI
Brainstorm Cell Therapeutics
N/A$1.08
+4.9%		N/A+28.7%$12.29MN/AN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Why This Small AI Company Holds 150 Patents
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel
No Wallstreet. No Advisor. No Problem.
Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...
Awesomely | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel